Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2025-06-05 00:00:00 ET · period of report 2025-06-04 · accession 0001562180-25-004491 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-06-05 | 2025-06-04 | AKBA | Malabre Richard C | SVP, CAO | S - Sale | $3.53 | -13.3K | 266.9K | -5% | -$47.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-04 | S | D | 13,334 | $3.53 | 266,914 | D | — | — | (F1) This sale was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the Reporting Person on December 12, 2024. (F2) The shares were sold at prices ranging from $3.50 to $3.60 and the price reported reflects the weighted average sale price. |